Eisai and Biogen Idec pool Alzheimer's efforts

Eisai and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai's clinical pipeline candidates for Alzheimer's disease, E2609 and BAN2401. The agreement also gives Eisai an option to jointly develop and commercialize two of Biogen Idec's candidates for Alzheimer’s disease, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.